Malin Corporation appoints Dr Kirsten Drejer and Luke Corning to its Board as Non-Executive Directors alongside CEO Darragh Lyons as Executive Director

– IRELAND, Dublin –  Malin Corporation Plc (ISE: MLC | LON: IRSH), a company investing in highly innovative life sciences companies, today announced the appointment of Dr Kirsten Drejer and Luke Corning as Non-Executive Directors and CEO Darragh Lyons as Executive Director, effective from 24 March 2020.

“On behalf of the Malin Board, I am delighted to welcome Dr Kirsten Drejer and Luke Corning as Non-Executive Directors, who bring highly relevant skills and experience to Malin. Recognising the importance of strong leadership at an executive level, we appointed Darragh Lyons to the role of CEO in September 2019, who also now joins the Board. I am confident that the new appointments will add quality and depth to Malin’s healthcare focus and governance framework as we look forward to important and value-enhancing milestones across our investee companies in 2020.” said Chairman Liam Daniel.

Dr Kirsten Drejer

Dr Kirsten Drejer founded and served as CEO of Symphogen, a Danish private biopharmaceutical company, and has extensive board experience on both private and public companies across the life sciences sector, including Zealand Pharma, where she currently serves as vice-chairman of the board, Bioporto and Alligator Bioscience.

About Luke Corning

Luke Corning is head of the Credit and Special Situations group at Pentwater Capital Management LP. Pentwater holds a 26% economic interest in Malin through a number of counterparties, as announced in October 2019. Over the course of his investment management career, Mr Corning has served on the boards of several private and public companies across a range of sectors.

About Darragh Lyons

Darragh Lyons

was appointed CEO of Malin in September 2019 having previously held the positions of Chief Business and Financial Officer, and Chief Financial Officer of Malin.

About Malin Corporation

Malin is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.